Potentially “groundbreaking” FDA gene therapy pathway leaves key issues unresolved
The US Food and Drug Administration’s (FDA’s) new pathway for gene therapies could be “groundbreaking” if applied broadly, though the…
Interviews
FDA’s latest CGT guidance streamlines path for in vivo CAR-T development
Animal testing alternatives to dominate, but not overnight
Walgreens sets sights on clinical trial network growth in recruitment drive
FDA genAI reviews hinge on clarity of dossiers
Synthetic control arms: full impact yet to be realised
Are DCTs truly more sustainable?
Podcast: How will biotech and biopharma manage with more funding cuts?
